United Drugs Stock Rating Reaffirmed by N+1 Singer (UDG)
United Drugs (LON:UDG)‘s stock had its “buy” rating restated by equities researchers at N+1 Singer in a research report issued on Tuesday, AnalystRatingsNetwork reports. They currently have a GBX 320 ($5.00) price objective on the stock. N+1 Singer’s price target would indicate a potential downside of 4.48% from the stock’s previous close.
United Drugs (LON:UDG) opened at 336.10 on Tuesday. United Drugs has a one year low of GBX 208.00 and a one year high of GBX 361.80. The stock’s 50-day moving average is GBX 344.5 and its 200-day moving average is GBX 313.5. The company’s market cap is £805.8 million.
UDG has been the subject of a number of other recent research reports. Analysts at Nplus1 Brewin reiterated a “buy” rating on shares of United Drugs (LON:UDG) in a research note to investors on Tuesday. They now have a GBX 320 ($5.00) price target on the stock. Separately, analysts at Davy Research reiterated an “outperform” rating on shares of United Drugs (LON:UDG) in a research note to investors on Friday, August 30th.
One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of GBX 342.50 ($5.35).
United Drug plc is a provider of services to healthcare manufacturers and pharmaceutical retailers, with operations in the United Kingdom, Ireland, the Netherlands, Belgium and the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.